Human Growth Hormone Market Size, Share & Trends Analysis Report By Product (Short-acting Growth Hormones, Long-acting Growth Hormones), By Applications (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Human Growth Hormone Market Size

The global human growth hormone market size was valued at USD 7.62 billion in 2025 and is projected to grow from USD 8.53 billion in 2026 to USD 20.96 billion by 2034, registering a CAGR of 11.9% during the forecast period from 2026 to 2034. North America dominated the human growth hormone market with a market share of 41.6% in 2025.

Somatotropin, or human growth hormone, is a peptide hormone generated by the pituitary gland that controls cell development, regeneration and repair, reproduction, and metabolism, all of which are necessary for total human growth. Growth hormone levels in the human body should be adequate for proper growth and can be influenced by physical activity, sleep quality, stress, and low blood sugar levels. Human growth hormones are also involved in bodily fluid balance, sugar and fat metabolism, bone and muscle growth, and injury healing. It also enhances the performance and strength of the muscles.

Product Insights

The global market is bifurcated into short-acting growth hormones and long-acting growth hormones. The short-acting growth hormones segment is the highest contributor to the market and is anticipated to grow at a CAGR of 18.60% over the forecast period. The standard of care for growth hormone shortage for a very long time has been the daily administration of short-acting growth hormones. Due to the rising prevalence of growth hormone deficiency and the availability of numerous products, including Saizen (Merck & Co. Inc.), Humatrope (Eli Lilly & Co.), Genotropin (Pfizer Inc.), and Norditropin (Novo Nordisk A/S), among others, the market for this segment is predicted to grow significantly over the forecast period. These short-acting growth hormone therapies have received approval for reasons like growth hormone deficit, Turner syndrome, idiopathic short stature, and small for gestational age. Because these items have been available since 1985, the market is already saturated. Additionally, the major players are making smart moves to enter the industry.

The new growth hormone class, long-acting growth hormones, offers less frequent administration, better patient compliance, and convenience. Due to new launches in key markets and a strong product pipeline, the segment is predicted to increase quickly throughout the projection period. Ascendis Pharma A/S reported in January 2022 that SKYTROFA had received E.C. approval for marketing authorization as a therapy for growth failure in children and adolescents aged 3 to 18. Key players are also working on creating unique long-acting products. For instance, Ngenla is being developed by Pfizer, Inc. and OPKO Health, Inc. In addition, Pfizer received a favorable CHMP opinion from EMA in December 2021, allowing them to commercialize their product in the E.U. to treat growth hormone insufficiency in children and adolescents.

Request Customizationto receive a tailored report.

Application Insights

The global market is bifurcated into growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, small for gestational age, and others. The growth hormone deficiency segment owns the highest human growth hormone market share and is anticipated to grow at a CAGR of 13.50% over the forecast period. Even though growth hormone insufficiency causes low stature, the issue was not recognized until the early 1900s. Insufficient production of human growth hormone is mainly brought on by pituitary gland malfunction. In 1985, synthetic growth hormones were first made available. The pituitary gland's activity is regulated and stimulated by these recombinant growth hormones. According to research, one in every 3,500 children was found to have a growth hormone deficit. Physiological performance is typically decreased in older persons with HGH deficits. It interferes with lipid metabolism, raises visceral fat, decreases muscle mass and bone density, and generally lowers the quality of life.

Adult growth hormone deficiency is brought on by insufficient anterior pituitary gland growth hormone production. This may be caused by a pituitary tumor, radiotherapy, a severe head injury, an inflammatory condition, or an obstruction of the pituitary gland's blood supply. These hormones have overall metabolic effects and enhance physical and mental performance. Additionally, the launch of novel long-acting growth hormones and the development of new products could accelerate market expansion due to greater usage and show the advantages of once-weekly administration. For instance, Hanmi Pharm is developing Efpegsomatropin. Co., Ltd. to treat people who lack growth hormones. Clinical trials for efpegsomatropin are currently in phase 2.

The pituitary gland's lack of growth hormone production during childhood leads to pediatric growth hormone insufficiency. With early diagnosis and treatment, children typically reach relatively standard heights and levels of development. Blood transports growth hormones throughout the body to carry out intricate processes, chief among them growth in youngsters. Although pediatric growth hormone insufficiency can be acquired or genetic, most instances still have no recognized etiology.

Distribution Channels Insights

The market is bifurcated into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. The hospital pharmacies segment is the highest contributor to the market and is anticipated to grow at a CAGR of 14.00% over the forecast period. Due to increased patient visits, follow-ups, and diagnoses of growth hormone insufficiency, the hospital pharmacy market is predicted to experience significant growth throughout the projection period. In the United States, during the variable follow-up period, about 4,308 (63.2%) Medicaid patients and 9,625 (68.4%) commercial patients with growth hormone deficiency received somatropin treatment, while 36.8% of Medicaid and 31.6% of commercial patients went untreated, according to Journal of Managed Care. In addition, Medicaid patients received 41.5 treated patients for every 100 person-years, compared to 55.4 treated patients for commercial patients.

The extensive availability of major drugstore chains, including Walgreens, Walmart, CVS Caremark, and others, and other reasons, suggest that the retail pharmacy industry will grow throughout the projected period. However, retail pharmacies are permitted to fill prescriptions for around 30 days. The retail pharmacy service more conveniently meets short-term prescription needs. Genotropin, Norditropin, Omnitrope, Saizen, and Zomacton, among other medications, are exclusively covered by pharmacy benefit programs, according to Blue Cross Blue Shield Association.

The segment for internet pharmacies is anticipated to increase at the fastest rate over the forecast period. The online pharmacy platform promotes safety and social seclusion. Due to the comfort, flexibility, and convenience that the platform provides, the trend of online shopping is expanding. This is boosting the category and resulting in significant sales. Additionally, clients can benefit from various discounts offered by online purchasing. These factors are anticipated to fuel demand for online pharmacies.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global human growth hormone market shareholder and is expected to grow at a CAGR of 12.50% over the forecast period. Due to excellent reimbursement conditions, an established healthcare infrastructure, considerable government initiatives, and rising healthcare awareness, North America is predicted to make up the most significant portion of the market. The presence of major firms in the area also facilitates greater access to innovative medications, which benefits the North American market. Several significant companies with U.S. headquarters, including Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., provide a variety of human G.H. medicines in the region.

• According to the American Academy of Pediatrics, growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the United States. The treatment of chronic renal failure, growth hormone deficiency (GHD), gestational age or intrauterine growth retardation, Turner's syndrome, Prader-Willi syndrome, and cachexia in the U.S. has been made possible by the widespread availability of recombinant growth hormone. Additionally, growing public awareness of growth hormone deficiency and its treatment is anticipated to accelerate market expansion. For instance, to raise awareness about the early detection and treatment of growth hormone disorders, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) observes Children's Growth Awareness Day each year.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Human Growth Hormone Market Trends

Asia-Pacific is anticipated to grow at a CAGR of 10.3% over the forecast period. By obtaining clearance and launching innovative products, a significant market share in potential Asia-Pacific nations like China and Japan is a goal for major firms. For instance, the phase III clinical trial of the pharmaceutical company Novo Nordisk A/HGH S's somapacitan, which is indicated for treating adult growth hormone insufficiency, was started in Japan in March 2017. Due to their large populations, China and India will likely grow into important opportunistic nations for healthcare in the coming years. As a result, pharmaceutical companies, including those that sell HGH medications, are making significant investments in these countries. Recombinant DNA technology is used in the development and production of numerous medicines. These medications primarily treat growth hormone deficiency in adults and children.

List of Key and Emerging Players in Human Growth Hormone Market